Showing 2781-2790 of 3597 results for "".
- AARS Scholar Grant to Be Used for Antibiotics Researchhttps://practicaldermatology.com/news/aars-scholar-grant-be-used-antibiotics-research/2470665/The American Acne and Rosacea Society (AARS) announced that the 2024 AARS Clinical Research Scholar Grant has been provided to Jean McGee, MD, PhD, of the Department of Dermatology at Brigham and Women’s Hospital in Boston. Additionally, AARS Clinical Research Grants are being provided to
- FDA Approves Tapinarof Cream, 1%, for ADhttps://practicaldermatology.com/news/fda-approves-tapinarof-cream-1-ad/2470664/The US Food and Drug Administration (FDA) approved tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, for an additional indication of the topical treatment of atopic dermatitis (AD) in adults and pediatric patients 2 years of age and older, Organon announced. Organon received the FDA appr
- Veradermics Gets New Financing for AGA/PHL Candidatehttps://practicaldermatology.com/news/veradermics-gets-new-financing-agaphl-candidate/2468761/Veradermics announced the closing of a $75 million Series B financing, proceeds of which will be used to fund the ongoing clinical development of the company’s lead candidate VDPHL01 for the treatment of androgenetic alopecia (AGA), or pattern hair loss (PHL). "The initiation of our pivota
- GW SMHS Teledermatology Program Receives Renewed Fundinghttps://practicaldermatology.com/news/gw-smhs-teledermatology-program-receives-renewed-funding/2468756/The George Washington University School of Medicine and Health Sciences Department of Dermatology, in collaboration with the Pennsylvania Avenue Baptist Church and the National Psoriasis Foundation (NPF), announced a renewed funding commitment of $350,000 from Johnson & Johnson in support of
- Report: Global Atopic Dermatitis Market Poised for Rapid Expansionhttps://practicaldermatology.com/news/report-global-atopic-dermatitis-market-poised-rapid-expansion/2468755/The atopic dermatitis (AD) market is forecasted to grow from $5.3 billion in 2021 to $22.6 billion by 2031, with a compound annual growth rate (CAGR) of 15.1%, according to a new report. North America as the current market leader, according to a press release from Allied Market Research,
- SDPA: Strategic Supplement Strategies for the Derm PAhttps://practicaldermatology.com/news/sdpa-strategic-supplement-strategies-derm-pa/2468638/Sara Wilchowski, DMSc, MPAS, PA-C, presented “Strategic Supplement Strategies for the Derm PA” at SDPA’s 22nd Annual Fall Dermatology Conference in Las Vegas. The lecture explored the role of nutraceuticals and alternative medicines in supporting patients in their overall wellness jour
- Acne Insights: Strategies and Solutions at 2024 SDPA Fallhttps://practicaldermatology.com/news/acne-insights-strategies-and-solutions-2024-sdpa-fall/2468634/The SDPA’s 22nd Annual Fall Dermatology Conference was held last week at the Fontainebleau in Las Vegas. Conference Medical Director Hilary Baldwin, MD, joined Shanna Miranti, MPAS, PA-C, in a discussion called “Acne Insights: Expert Strategies and Solutions from the Pros.” The presentatio
- Roflumilast Cream 0.15% Receives Glamour's Best Eczema Product Award for 2024https://practicaldermatology.com/news/roflumilast-cream-015-receives-glamours-best-eczema-product-award-2024/2468585/Arcutis Biotherapeutics announced today that ZORYVE® (roflumilast) cream 0.15% has been named Best Eczema Product by Glamour magazine in its 2024 Health and Wellness Awards. The cream, which is the first once-daily FDA-approved topical treatment specifically indicated for mild to
- Study: Botanical Gummies Show Promise for Thinning Hairhttps://practicaldermatology.com/news/study-botanical-gummies-show-promise-thinning-hair/2468582/A recent 6-month study found that a daily gummy supplement with B vitamins, zinc, and botanicals improved hair density, strength, and perceived hair quality in women with thinning hair. Researchers for the double-blind, placebo-controlled trial included 65 healthy female participants aged
- Rademikibart 'Could Be Incredibly Important for Type 2'https://practicaldermatology.com/news/rademikibart-could-be-incredibly-important-type-2/2468551/A second-generation IL-4Rα inhibitor known as rademikibart shows promise for further elevating the standard of care for type 2 inflammatory conditions in the future, Dr. Christopher Bunick said during a presentation at the 44th Annual Fall Clinical Dermatology Conference. Dr. Bunick showed